GlassScriptPhysician profile
Jaroslaw Jac
NPI 1326029802
$845.41
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $614 · 2020: $12.74 · 2021: $11.92 · 2022: $26.37 · 2024: $181.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $159 · Education: $21.31.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $159.21 |
| Education | $21.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $109.84 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $97.94 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $87.52 | 2019-2024 | Opdivo, Opdualag |
| Lilly USA, LLC | $84.93 | 2019 | |
| Janssen Biotech, INC. | $82.73 | 2019 | |
| Merck Sharp & Dohme LLC | $49.49 | 2019 | |
| Amgen INC. | $43.05 | 2019-2020 | |
| Array Biopharma INC | $33.63 | 2024 | Mektovi, Braftovi, Lorbrena |
| Celgene Corporation | $30.16 | 2024 | |
| Puma Biotechnology, INC. | $29.73 | 2019 | |
| Abbvie INC. | $29.65 | 2024 | |
| Adaptive Biotechnologies Corporation | $27.03 | 2024 | Clonoseq |
| Pharmacyclics LLC, An Abbvie Company | $26.37 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.14 | 2019 | |
| Novartis Pharmaceuticals Corporation | $19.98 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $18.91 | 2019 | |
| Alexion Pharmaceuticals, INC. | $18.62 | 2024 | Ultomiris |
| Gilead Sciences, INC. | $11.92 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.37 | 2019 | |
| Clovis Oncology, INC. | $10.40 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jaroslaw Jac listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.